Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 7:00AM
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”)
(Nasdaq: FNCH), a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel
class of orally administered biological drugs, today announced that
Mark Smith, PhD, Chief Executive Officer, will present a company
overview at the H.C. Wainwright 23rd Annual Global Investment
Conference being held September 13-15, 2021. The on-demand
presentation will be available on Monday, September 13, 2021 at
7:00 am ET.
A webcast of the presentation will be available
under the ‘Investors & News’ section of the Finch website and
will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage
microbiome therapeutics company leveraging its Human-First
Discovery® platform to develop a novel class of orally administered
biological drugs. With the capabilities to develop both complete
and targeted microbiome therapeutics, Finch is advancing a rich
pipeline of candidates designed to address a wide range of unmet
medical needs. Finch’s lead candidate, CP101, is in late-stage
clinical development for the prevention of recurrent C. difficile
infection (CDI), and has received Breakthrough Therapy and Fast
Track designations from the U.S. Food and Drug Administration. In
June 2020, Finch announced that CP101 met its primary efficacy
endpoint in PRISM3, the first of two pivotal trials to support the
development of CP101 for the prevention of recurrent CDI. PRISM4, a
Phase 3 trial, is designed to serve as the second pivotal trial of
CP101 for recurrent CDI. Finch is also developing CP101 for the
treatment of chronic hepatitis B virus, and FIN-211 for the
treatment of the gastrointestinal and behavioral symptoms of autism
spectrum disorder. Finch has a partnership with Takeda focused on
the development of targeted microbiome therapeutics for
inflammatory bowel disease.
Human-First Discovery® is a registered trademark
of Finch Therapeutics Group, Inc.
Investor Contact:
Laurence WattsGilmartin Group(619)
916-7620laurence@gilmartinir.com
or
Stephen JasperGilmartin Group(858)
525-2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public
Relationsjurban@berrypr.com 212-253-8881
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Finch Therapeutics (NASDAQ:FNCH)
Historical Stock Chart
From Jul 2023 to Jul 2024